NCT05720325View on ClinicalTrials.gov

Dupilumab Effects Against Aeroallergen Challenge

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Asthma, Allergic
Interventions
DRUG

Dupilumab

Dupixent is an interleukin-4 receptor alpha antagonist

OTHER

House Dust Mites (HDM)

House Dust Mites used to challenge subjects using an aeroallergen challenge chamber

OTHER

Placebo

Inert placebo administered to placebo arms of study.

Trial Locations (2)

78229

RECRUITING

Biogenics Research Chamber, San Antonio

RECRUITING

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT05720325 - Dupilumab Effects Against Aeroallergen Challenge | Biotech Hunter | Biotech Hunter